Brain 11C-ITMM PET to longitudinally assess type 1 metabotropic glutamate receptor availability in Alzheimer's disease

IF 2.3 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Neuroimaging Pub Date : 2021-06-18 DOI:10.1111/jon.12895

Kenji Ishibashi, Yoshiharu Miura, Kei Wagatsuma, Masashi Kameyama, Kenji Ishii

{"title":"Brain 11C-ITMM PET to longitudinally assess type 1 metabotropic glutamate receptor availability in Alzheimer's disease","authors":"Kenji Ishibashi, Yoshiharu Miura, Kei Wagatsuma, Masashi Kameyama, Kenji Ishii","doi":"10.1111/jon.12895","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>Little evidence exists on the role of type 1 metabotropic glutamate receptor (mGluR1) in the pathophysiology of Alzheimer's disease (AD), although mGluR1 may be involved in the regulation of neuronal excitability and synaptic plasticity. We have recently reported that mGluR1 availability in the early stage of AD is equivalent to that in healthy subjects. This study aimed to address whether mGluR1 availability changes with the progression of AD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Eight patients with AD (79.1 ± 4.6 years) underwent a total of two positron emission tomography (PET) examinations using the mGluR1 radioligand during the early-to-middle stages of AD. The mean interval was 2.8 years. Volumes-of-interest were placed on the frontal, parietal, and temporal cortices, hippocampus, anterior and posterior lobes, and vermis in the cerebellum. The binding potential (BP<sub>ND</sub>) was calculated to estimate mGluR1 availability, applying partial volume correction to the BP<sub>ND</sub> values.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>No significant difference was observed in BP<sub>ND</sub> values between the first and second PET examinations in the frontal cortex (<i>p</i> = 0.94), parietal cortex (<i>p</i> = 0.67), temporal cortex (<i>p</i> = 0.20), hippocampus (<i>p</i> = 0.17), anterior lobe (<i>p</i> = 0.73), posterior lobe (<i>p</i> = 0.21), and vermis (<i>p</i> = 0.22).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study suggests that mGluR1 availability is unchanged in the follow-up period of a few years during the early-to-middle stages of AD.</p>\n </section>\n </div>","PeriodicalId":16399,"journal":{"name":"Journal of Neuroimaging","volume":"31 5","pages":"864-868"},"PeriodicalIF":2.3000,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/jon.12895","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroimaging","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jon.12895","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background and Purpose

Little evidence exists on the role of type 1 metabotropic glutamate receptor (mGluR1) in the pathophysiology of Alzheimer's disease (AD), although mGluR1 may be involved in the regulation of neuronal excitability and synaptic plasticity. We have recently reported that mGluR1 availability in the early stage of AD is equivalent to that in healthy subjects. This study aimed to address whether mGluR1 availability changes with the progression of AD.

Methods

Eight patients with AD (79.1 ± 4.6 years) underwent a total of two positron emission tomography (PET) examinations using the mGluR1 radioligand during the early-to-middle stages of AD. The mean interval was 2.8 years. Volumes-of-interest were placed on the frontal, parietal, and temporal cortices, hippocampus, anterior and posterior lobes, and vermis in the cerebellum. The binding potential (BP_ND) was calculated to estimate mGluR1 availability, applying partial volume correction to the BP_ND values.

Results

No significant difference was observed in BP_ND values between the first and second PET examinations in the frontal cortex (p = 0.94), parietal cortex (p = 0.67), temporal cortex (p = 0.20), hippocampus (p = 0.17), anterior lobe (p = 0.73), posterior lobe (p = 0.21), and vermis (p = 0.22).

Conclusion

This study suggests that mGluR1 availability is unchanged in the follow-up period of a few years during the early-to-middle stages of AD.

查看原文本刊更多论文

大脑11C-ITMM PET纵向评估阿尔茨海默病中1型代谢型谷氨酸受体的可用性

背景和目的关于1型代谢型谷氨酸受体（mGluR1）在阿尔茨海默病（AD）的病理生理学中的作用，尽管mGlu1可能参与神经元兴奋性和突触可塑性的调节，但证据很少。我们最近报道，mGluR1在AD早期的可用性与健康受试者的可用性相当。本研究旨在探讨mGluR1的可用性是否随AD的进展而变化。方法8例AD患者（79.1±4.6岁）在AD的早期至中期接受了两次使用mGluR1-放射性配体的正电子发射断层扫描（PET）检查。平均检查间隔为2.8年。感兴趣的体积被放置在额叶、顶叶和颞叶皮质、海马体、前叶和后叶以及小脑的朱砂上。计算结合电位（BPND）以估计mGluR1的可用性，对BPND值进行部分体积校正。结果第一次和第二次PET检查在额叶（p=0.94）、顶叶（p=0.67）、颞叶（p=0.20）、海马（p=0.17）、前叶（p=0.73）、后叶（p=0.21），结论本研究表明，在AD的早期至中期，mGluR1的可用性在几年的随访期内没有变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroimaging 医学-核医学

CiteScore

4.70

自引率

0.00%

发文量

117

审稿时长

6-12 weeks

期刊介绍： Start reading the Journal of Neuroimaging to learn the latest neurological imaging techniques. The peer-reviewed research is written in a practical clinical context, giving you the information you need on: MRI CT Carotid Ultrasound and TCD SPECT PET Endovascular Surgical Neuroradiology Functional MRI Xenon CT and other new and upcoming neuroscientific modalities.The Journal of Neuroimaging addresses the full spectrum of human nervous system disease, including stroke, neoplasia, degenerating and demyelinating disease, epilepsy, tumors, lesions, infectious disease, cerebral vascular arterial diseases, toxic-metabolic disease, psychoses, dementias, heredo-familial disease, and trauma.Offering original research, review articles, case reports, neuroimaging CPCs, and evaluations of instruments and technology relevant to the nervous system, the Journal of Neuroimaging focuses on useful clinical developments and applications, tested techniques and interpretations, patient care, diagnostics, and therapeutics. Start reading today!